Pain: a prevalent feature in patients with mucopolysaccharidosis
Results of a cross-sectional national survey
Background While clinical observations suggest that many patients with mucopolysaccharidosis (MPS) experience chronic pain, few studies have assessed its extent and impact. We therefore investigated its prevalence in patients with all types of MPS in the Netherlands. We also examined the association between pain and health related quality of life (HRQoL) and other clinical variables. Methods We conducted a nationwide MPS survey that used questionnaires on MPS and disease-related symptoms (MPS-specific questionnaire), developmental level (Vineland Screener 0-6 years), quality of life (PedsQl and SF-36), and disability (Childhood Health Assessment Questionnaire). Depending on their age and developmental level, patients or their parents were asked to assess pain by keeping a pain diary for five consecutive days: either the Non-communicating Children's Pain Checklist - Revised (3-18 years intellectually disabled and children <8 years), the VAS-score (> 18 years), or the Faces Pain Scale - Revised (8-18 years). Results Eighty-nine MPS patients were invited, 55 of whom agreed to participate (response rate 62 %; median age 10.9 years, range 2.9-47.2 years). They covered a wide spectrum in all age groups, ranging from no pain to severe pain. Forty percent scored above the cut-off value for pain. Most reported pain sites were the back and hips. While the MPS III group experienced the highest frequency of pain (52.9 %), 50 % of patients with an intellectual disability seemed to experience pain, versus 30 % of patients with a normal intelligence. MPS patients scored much lower (i.e., more pain) than a random sample of the Dutch population on the bodily pain domain of the SF-36 scale and the PedsQl. Conclusion With or without intellectual disabilities, many MPS patients experience pain. We recommend that standardized pain assessments are included in the regular follow-up program of patients with MPS.
|Journal of Inherited Metabolic Disease|
|This work was funded by the European Commission 7th Framework Programme; grant id fp7/304999 - Clinical trial of gene therapy for MPS VI - a severe lysosomal storage disorder (MEUSIX)|
|Organisation||Department of Internal Medicine|
Brands, M.M.M.G, Güngör, D, van den Hout, J.M.P, Karstens, F.P.J, Oussoren, E, Plug, I, … van der Ploeg, A.T. (2014). Pain: a prevalent feature in patients with mucopolysaccharidosis. Journal of Inherited Metabolic Disease. doi:10.1007/s10545-014-9737-0